Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease
Joint Authors
Nguyen, Geoffrey C.
Rumman, Amir
Candia, Roberto
Sam, Justina J.
Croitoru, Kenneth
Silverberg, Mark S.
Steinhart, A. Hillary
Source
Canadian Journal of Gastroenterology and Hepatology
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-01-23
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD).
Methods.
We conducted a retrospective cohort study of IBD patients who were prescribed anti-TNF therapy (2007–2014) in Ontario.
We assessed if the insurance type was a predictor of timely access to anti-TNF therapy and nonroutine health utilization (emergency department visits and hospitalizations).
Results.
There were 268 patients with IBD who were prescribed anti-TNF therapy.
Public drug coverage was associated with longer median wait times to first dose than private one (56 versus 35 days, P=0.002).
After adjusting for confounders, publicly insured patients were less likely to receive timely access to anti-TNF therapy compared with those privately insured (adjusted hazard ratio, 0.66; 95% CI: 0.45–0.95).
After adjustment for demographic and clinical characteristics, publicly funded subjects were more than 2-fold more likely to require hospitalization (incidence rate ratio [IRR], 2.30; 95% CI: 1.19–4.43) and ED visits (IRR 2.42; 95% CI: 1.44–4.08) related to IBD.
Conclusions.
IBD patients in Ontario with public drug coverage experienced greater delays in access to anti-TNF therapy than privately insured patients and have a higher rate of hospitalizations and ED visits related to IBD.
American Psychological Association (APA)
Rumman, Amir& Candia, Roberto& Sam, Justina J.& Croitoru, Kenneth& Silverberg, Mark S.& Steinhart, A. Hillary…[et al.]. 2017. Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology،Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1141463
Modern Language Association (MLA)
Rumman, Amir…[et al.]. Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology No. 2017 (2017), pp.1-8.
https://search.emarefa.net/detail/BIM-1141463
American Medical Association (AMA)
Rumman, Amir& Candia, Roberto& Sam, Justina J.& Croitoru, Kenneth& Silverberg, Mark S.& Steinhart, A. Hillary…[et al.]. Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology. 2017. Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1141463
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141463